ReviewBritish journal of clinical pharmacology2012
Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases.
Review in British journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 154 citations in OpenAlex.
- Efficacy and safety of tripterygium glycosides for active moderate to severe Graves' ophthalmopathy: a randomised, observer-masked, single-centre trial.European journal of endocrinology · 2021Trial
- Oxymatrine therapy inhibited epidermal cell proliferation and apoptosis in severe plaque psoriasis.The British journal of dermatology · 2019Trial
- Efficacy and safety of Tripterygium wilfordii hook F versus acitretin in moderate to severe psoriasis vulgaris: a randomized clinical trial.Chinese medical journal · 2015Trial
- Triptolide exerts antiviral effects and alleviates influenza A‑induced pneumonia by inhibiting the overactivation of absent in melanoma 2 signaling in immune cells.International journal of molecular medicine · 2026Article
- Effects of (5R)-5-Hydroxytriptolide Against Rheumatoid Arthritis: Intervention on the Transformation of Bone Marrow Cells Induced Osteoclasts Bone Erosion and Angiogenesis.Applied biochemistry and biotechnology · 2026Article
- Tripterygium glycosides: recent advances in mechanisms, therapeutic applications, and safety optimization.Frontiers in medicine · 2026Review
- From immunosuppression to immune reprogramming: is triptolide a potential "immune reset" agent in autoimmune diseases?Immunologic research · 2025Review
- Cordycepin Ameliorates Psoriasis-Like Skin Lesion by Regulating p53/MDM2 Feedback Loop.Molecular biotechnology · 2025Article
- Breaking the psoriasis pathological signaling cycle: A novel nanomedicine strategy targeting metabolism and oxidative stress.Materials today. Bio · 2025Article
- Successful Treatment of Ixekizumab-Induced Paradoxical Eczematous Reaction with JAK Inhibitors: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- TP-P1-Loaded Thermosensitive Hydrogel Attenuates Rheumatoid Arthritis in a Mouse Model via TLR4/NF-κB Pathway.Journal of inflammation research · 2025Article
- Edible bird's nest improves the premature ovarian failure induced by tripterygium glycosides.Food science & nutrition · 2024Article
- Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients.Frontiers in medicine · 2024Article
- Triptolide induces PANoptosis in macrophages and causes organ injury in mice.Apoptosis : an international journal on programmed cell death · 2023Article
- Article
- Therapeutic interventions target the NLRP3 inflammasome in ulcerative colitis: Comprehensive study.World journal of gastroenterology · 2023Review
- Comprehensive Analysis to Identify Rh Family C Glycoprotein (Drug design, development and therapy · 2023Article
- Article
- The Anti-Inflammatory and Immunomodulatory Activities of Natural Products to Control Autoimmune Inflammation.International journal of molecular sciences · 2022Review
- Dendritic cell combination therapy reduces the toxicity of triptolide and ameliorates colitis in murine models.Drug delivery · 2022Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apart from cancer chronic (auto)immune-mediated diseases are a major threat for patients and a challenge for physicians. These conditions include classic autoimmune diseases like systemic lupus erythematosus, systemic sclerosis and dermatomyositis and also immune-mediated inflammatory diseases such as rheumatoid arthritis and psoriasis. Traditional therapies for these conditions include unspecific immunosuppressants including steroids and cyclophosphamide, more specific compounds such as ciclosporin or other drugs which are thought to act as immunomodulators (fumarates and intravenous immunoglobulins). With increasing knowledge about the underlying pathomechanisms of the diseases, targeted biologic therapies mainly consisting of anti-cytokine or anti-cytokine receptor agents have been developed. The latter have led to a substantial improvement of the induction of long term remission but drug costs are high and are not affordable in all countries. In China an extract of the herb Tripterygium wilfordii Hook F. (TwHF) is frequently used to treat autoimmune and/or inflammatory diseases due to its favourable cost-benefit ratio. Triptolide has turned out to be the active substance of TwHF extracts and has been shown to exert potent anti-inflammatory and immunosuppressive effects in vitro and in vivo. There is increasing evidence for an immunomodulatory and partly immunosuppressive mechanism of action of triptolide. Thus, compounds such as triptolide or triptolide derivatives may have the potential to be developed as a new class of drugs for these diseases. In this review we summarize the published knowledge regarding clinical use, pharmacokinetics and the possible mode of action of triptolide in the treatment of inflammatory diseases with a particular focus on psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.